Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

14.12.2022 - MIAMI, Dec. 14, 2022 (GLOBE NEWSWIRE) - Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and ... Seite 1

Related Keywords

Japan ,Turkey ,Japanese ,Jayd Kranzler , ,Chief Executive Officer ,Urica Sponsored Phase ,